Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.50 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca, GlaxoSmithKline, and Merck Sharp & Dohme Corp

Oncology Town Hall®: Primary Investigators Present Key Abstracts in Gynecologic Cancer Management

Release Date: September 15, 2020
Expiration Date: September 15, 2021

Activity Overview

Gynecologic malignancies are an important cause of morbidity and mortality for women in the United States. Patients with ovarian cancer are frequently diagnosed at an advanced stage for which the 5-year survival rate is dismal. Early-stage management of cervical and endometrial cancer is generally managed effectively by hysterectomy, but for patients with locally advanced or metastatic disease, the choices are less certain. Poly(ADP-ribose) polymerase (PARP) inhibitors are a major recent advancement that have changed the treatment landscape for ovarian cancer. PARP inhibitors are also being investigated in other tumor types. Targeted therapy, immunotherapy, and combined therapeutic strategies are also under active investigation in gynecological malignancies.

This activity provides an update on the most recent data from key abstracts presented at major cancer conferences. Hear experts in the field assess and discuss how to apply these findings to clinical practice to improve care for patients with gynecologic malignancies.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca, GlaxoSmithKline, and Merck Sharp & Dohme Corp

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is directed toward oncologists and fellows who treat patients with gynecologic cancers. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of gynecologic cancers will be invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Evaluate recently reported clinical trial data applicable to the care of patients with gynecologic cancers
  • Integrate emerging data into a plan of care to optimize outcomes for patients with gynecologic cancer.
  • Assess the design and patient eligibility for ongoing gynecologic cancer clinical trials and treatment regimens under investigation.

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Bradley J. Monk, MD, FACOG, FACS
Bradley J. Monk, MD, FACOG, FACS
Professor and Director, Division of Gynecologic Oncology
Creighton University School of Medicine
St. Joseph’s Hospital and Medical Center
Medical Director, US Oncology Network – Gynecologic Oncology Research
Phoenix, AZ

Disclosures: Consultant: AbbVie, Advaxis, Amgen, AstraZeneca, Biodesix, Clovis Oncology, Genmab, Gradalis, ImmunoGen, Incyte Corporation, Insys Therapeutics, Mateon Therapeutics, Merck & Co, Myriad Genetics, Perthera, Pfizer, Precision Oncology, F. Hoffman-La Roche/Genentech, Samumed, Takeda, Tesaro, VBL Therapeutics. Speakers Bureau: AstraZeneca, Clovis Oncology, Janssen Pharmaceuticals/Johnson & Johnson, F. Hoffman-La Roche/Genentech, Tesaro.

Jubilee Brown, MD
Jubilee Brown, MD
Professor and Division Director
Division of Gynecologic Oncology
Levine Caner Institute, Atrium Health
Charlotte, NC

Disclosures: Jubilee Brown, MD has no relevant financial relationship with commercial interest to disclose.

Richard T. Penson, MD, MRCP
Richard T. Penson, MD, MRCP
Associate Professor of Medicine
Harvard Medical School
Clinical Director Medical Gynecologic Oncology
Massachusetts General Hospital
IRB Chair Dana-Farber Cancer Institute / Harvard Cancer Center
Boston, MA

Disclosures: Grant Research Support: Array BioPharma Inc., AstraZeneca, Eisai Co Inc., Genentech Inc, Regeneron Pharmaceuticals, Sanofi-Aventis US LLC, Tesaro Inc, Vascular Biogenics Ltd; Consultant: AbbVie, AstraZeneca, Cancer Panels, Care4ward (Unpaid), Genentech, lntellisphere, Merck & Co, Nexus Global Group, Pieris Pharmaceuticals Inc, Sutro Biopharma, Vascular Biogenics Ltd, WebMD

Kathleen Moore, MD
Kathleen Moore, MD
Associate Professor of Obstetrics and Gynecology
Jim and Christy Everest Endowed Chair in Cancer Research
The University of Oklahoma College of Medicine
Director of Clinical Research
Medical Director of the Clinical Trials Office
Stephenson Cancer Center
Oklahoma City, OK

Disclosures: Grant Research Support: Eli Lilly and Company, Merck & Co, PTC Therapeutics; Consultant: Aravive, AstraZeneca, Clovis Oncology, Eisai Co, Genentech/F. Hoffman-La Roche, GSK/Tesaro, ImmunoGen, Merck & Co, Tarveda Therapeutics, Vavotar Life Sciences.

Rachel N. Grisham, MD
Rachel N. Grisham, MD
Associate Attending Physician
Division of Solid Tumor Oncology
Section Head, Ovarian Cancer
Director, GMO Westchester
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Consultant: AbbVie; Speakers Bureau: OncLive, Prime

Leslie M. Randall, MD, MAS, FACS
Leslie M. Randall, MD, MAS, FACS
Director Division of Gynecologic Oncology
Department of Obstetrics and Gynecology
VCU Health Systems
Diane Harris Wright Professor of Gynecologic Oncology Research
Massey Cancer Center
Virginia Commonwealth University
Richmond, VA

Disclosures: Leslie Randall, MD, MAS, has no relevant financial relationships with commercial interests to disclose.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By